Aprepitant oral suspension kits recalled over potential metal particulates
Merck Sharp & Dohme is recalling 3 single-dose kits of Emend (aprepitant) for oral suspension over the potential presence of metal particulates in the product.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Scored 3 under the risk-of-harm criterion: metal particulates in an oral medicine are a stated physical contaminant, and no injuries are reported.
Plain-English summary
Merck Emend (aprepitant) for oral suspension, 125 mg, single-dose kit, manufactured by Novo Nordisk Production Ireland Limited of Athlone, Ireland for Merck Sharp & Dohme LLC of Rahway, New Jersey, under NDC 0006-3066-03, is being recalled.
The reason given in the enforcement record is the presence of particulate matter: the potential presence of metal particulates in the product.
The recall covers 3 single-dose kits from lot Z014503, expiry 11/15/2027. Distribution was nationwide in the USA. The FDA has classified the action as Class II.
Patients should not stop taking a prescribed medicine without speaking to their prescriber or pharmacist, who can confirm whether a specific kit is affected and arrange a replacement.
The recalled product
- Product
- EMEND (APREPITANT)
- Brand
- EMEND
- Manufacturer
- Merck Sharp & Dohme LLC
- Category
- Drug — Antiemetic
- Affected units
- 3
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: Z014503
- Exp 11/15/2027
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Merck Sharp & Dohme LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Merck Sharp & Dohme LLC
See all →- HighPosaconazole oral suspension recalled over potential metal particulates in the product
FDA (Drugs) · 2025-12-31
Same hazard · particulate matter
See all →- SevereFDA Recalls Argatroban Injection Vials Due to Particulate Matter
FDA (Drugs) · 2026-10-28
- SeverePar Health Recalls Argatroban Injection Vials Due to Particulate Matter
FDA (Drugs) · 2026-10-28
- ModerateIMAAVY Injection Recalled for Presence of Particulate Matter
FDA (Drugs) · 2026-10-14
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
Similar recalls
- ModerateAcetaminophen Oral Suspension Recalled Due to Contaminated Raw Ingredient
FDA (Drugs) · 2021-11-17
- ModerateChildren's Acetaminophen Oral Suspension Recalled for Contaminated Excipient
FDA (Drugs) · 2022-03-02
- HighBaxter ExactaMed Oral Dispenser Recalled for Particulate Matter Contamination
FDA (Devices) · 2023-04-26
- ModerateAscend Recalls Cephalexin Oral Suspension Due to CGMP Deviations
FDA (Drugs) · 2021-02-24
- ModerateAcetaminophen Child Strawberry Oral Suspension Recalled for Contaminated Excipient
FDA (Drugs) · 2022-03-02
- SevereAmerican Regent Recalls Atropine Sulfate Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26